Melanoma Cancer Stem Cells
Melanoma Cancer Stem Cells - Related Videos
12:16
Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
0 Views •
Cited by 22 •
2013
This article describes the preparation of freshly obtained melanoma tissue into primary cell cultures, and how to remove contaminations of erythrocytes and fibroblasts from the tumor cells. Finally, we describe how CD133+ putative melanoma stem cells are sorted from the CD133- bulk using Magnetic Activated Cell Sorting (MACS).
12:43
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
0 Views •
Cited by 15 •
2014
Evaluated in syngeneic immunocompetent hosts, cancer stem cell (CSC) based dendritic cell (DC) vaccine demonstrated significantly higher antitumor immunity than traditional DC vaccines pulsed with heterogeneous bulk tumor cells.
05:40
Melanoma Stem Cell Isolation: A Method to Obtain CD133 Positive and Negative Melanoma Cells Using Magnetic-activated Cell Sorting
0 Views •
2023
This video describes the technique of isolating CD133 negative and positive melanoma stem cells from a primary melanoma cell line using magnetic-activated cell sorting. The CD133 positive melanoma CSCs are further studied to understand the mechanisms of melanoma tumorigenesis.
10:03
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
0 Views •
Cited by 6 •
2016
The goal of this protocol is to show the protocol for reprogramming melanoma tumor-infiltrating lymphocytes into induced pluripotent stem cells.
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
0 Views •
Cited by 27 •
2015
Pancreatic cancer stem cells (CSCs) can be expanded in vitro using the anchorage-independent sphere culture technique, which represents a powerful tool to study CSC biology and can serve as the first step to develop novel CSC-targeting therapies. Here the methodology for expanding, analyzing and targeting of pancreatic CSCs is provided.
FAQs
These pathways can help melanoma cancer stem cells preserve self-renewal capacity while producing cellular diversity. Wnt, Notch, and Hedgehog are regulatory signaling systems rather than interchangeable markers, so examining them may reveal distinct mechanisms that support tumor maintenance. Their activity is relevant when researchers seek vulnerabilities that could complement treatments directed at more actively growing melanoma cells.
Quiescence can make a subpopulation less visible to strategies that primarily affect rapidly dividing cells. A temporarily inactive cell may later resume self-renewal, allowing tumor growth to re-emerge after treatment. This provides a mechanistic link between cellular state and relapse, and it explains why treatment resistance cannot be evaluated only by measuring the immediate loss of proliferating melanoma cells.
The tumor microenvironment can influence whether these cells survive and maintain stem-like behavior. Interactions with surrounding components may provide support during disease progression, although the relevant signals can vary across tumors. Studying the cells together with their microenvironment therefore offers a broader view of melanoma biology than examining tumor cells in isolation, particularly when investigating persistence and progression.
Markers are valuable because they may help researchers identify the subpopulation within a heterogeneous melanoma tumor. However, a marker does not by itself establish how a cell behaves or which vulnerability it carries. Linking marker patterns with self-renewal, treatment resistance, signaling activity, or tumor-regenerating capacity can clarify which features have biological and therapeutic significance.
Melanoma cancer stem cells are relevant to several stages of disease research, including tumor initiation, metastasis, and relapse. Their study allows investigators to ask whether a cell population can contribute to new tumor growth, support spread, or persist after treatment. These questions connect cellular behavior with clinically important patterns of progression and recurrence in melanoma medicine.
Combination treatment is a central implication of this research. A therapy aimed at rapidly dividing melanoma cells may need to be paired with an approach that addresses cells capable of regenerating the tumor. The goal is not simply greater drug exposure; it is to target complementary cellular states or vulnerabilities, potentially reducing persistence and treatment-associated recurrence.
An immediate reduction in tumor burden may not demonstrate elimination of the cells capable of renewing the tumor. Surviving cells may be quiescent, resistant, or supported by microenvironmental interactions, so later regrowth remains possible. Interpreting treatment outcomes through these mechanisms encourages researchers to examine persistence and regenerative capacity, not only short-term tumor response.